Restricted accessReview articleFirst published online 2024-11
Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis
To evaluate the comparative efficacy of pharmacological interventions for children and adolescents with a dual diagnosis of persistent tic disorders or Tourette disorder and attention-deficit/hyperactivity disorder (TD + ADHD).
Methods:
We searched CENTRAL, Embase, PubMed, PsycInfo, Web of Sciences, ClinicalTrials.gov, and WHO ICTRP up to September 2023 to identify double-blinded randomized controlled trials (RCTs) assessing pharmacological interventions for children and adolescents with TD + ADHD. Outcomes were change in ADHD symptoms (primary) and tics (secondary) severity. Standardized mean difference (SMD) was calculated and pooled in random-effects network meta-analysis. The Confidence in Network Meta-Analysis framework was adopted to determine certainty of evidence.
Results:
We included 8 RCTs involving 575 participants. Network meta-analyses demonstrated that α2 agonists (SMD, 95% confidence interval [CI] ADHD: −0.72 [−1.13 to −0.31]; TD: −0.70 [−0.96 to −0.45]) and stimulants + α2 agonists (ADHD: −0.84 [−1.54 to −0.13]; TD: −0.60 [−1.04 to −0.17]) were more efficacious than placebo for ADHD symptoms and tics severity. Stimulants alone were more efficacious than placebo for ADHD symptoms severity only, but they did not worsen tics (ADHD: −0.54 [−1.05 to −0.03]; TD: −0.22 [−0.49 to 0.05]). There were no significant differences between any pairs of medications that were found efficacious against placebo for ADHD symptoms or tics severity. Certainty in the evidence varied from low to very low.
Conclusions:
Stimulants are efficacious for ADHD symptoms severity and do not increase tics severity in TD + ADHD. α2 agonists are efficacious for both ADHD symptoms and tics severity in TD + ADHD. These findings should inform guidelines and help guide shared decision-making to choose a medication for children with TD + ADHD.
Get full access to this article
View all access options for this article.
References
1.
AllenAJ, KurlanRM, GilbertDL, et al.Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 2005; 65(12):1941–1949.
2.
BalduzziS, RückerG, SchwarzerG. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health, 2019; 22(4):153–160.
BlochMH, PanzaKE, Landeros-WeisenbergerA, et al.Meta-analysis: Treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry, 2009; 48(9):884–893.
5.
BussingR, FernandezM, HarwoodM, et al.Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: Psychometric properties and normative ratings from a school district sample. Assessment, 2008; 15(3):317–328.
6.
CastellanosFX, GieddJN, EliaJ, et al.Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: Effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry, 1997; 36(5):589–596.
7.
ChaimaniA, SalantiG. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods, 2012; 3(2):161–176.
8.
ChenY, KeZ, OuyangY, et al.Clonidine patch for Tourette syndrome with attention-deficit/hyperactivity disorder. Psychiatry Investig, 2024; 21(4):387–395.
9.
CoghillD, BanaschewskiT, CorteseS, et al.The management of ADHD in children and adolescents: Bringing evidence to the clinic: Perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry, 2021; 32(8):1337–1361.
10.
CohenSC, LeckmanJF, BlochMH. Clinical assessment of Tourette syndrome and tic disorders. Neurosci Biobehav Rev, 2013; 37(6):997–1007.
11.
ConnersCK, SitareniosG, ParkerJD, et al.Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol, 1998a;26(4):279–291.
CorrellCU, CorteseS, CroattoG, et al.Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: An umbrella review. World Psychiatry, 2021; 20(2):244–275.
14.
CorteseS. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med, 2020; 383(11):1050–1056.
15.
CorteseS, AdamoN, Del GiovaneC, et al.Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 2018; 5(9):727–738.
16.
CorteseS, HoltmannM, BanaschewskiT, et al.European ADHD Guidelines Group. Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry, 2013; 54(3):227–246.
17.
DuPaulGJ, PowerTJ, AnastopoulosAD, et al.ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY, USA: Guilford Press; 1998.
18.
EddyCM, CavannaAE, GulisanoM, et al.Clinical correlates of quality of life in Tourette syndrome. Mov Disord, 2011; 26(4):735–738.
19.
FarhatLC, BehlingE, Landeros-WeisenbergerA, et al.Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette’s Disorder: A systematic review and network meta-analysis. Lancet Child Adolesc Health, 2023; 7(2):112–126.
20.
FarhatLC, BlochMH. Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy—A commentary on Rodrigues et al. (2020). J Child Psychol Psychiatry, 2021; 62(6):701–703.
21.
FarhatLC, FloresJM, BehlingE, et al.The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: A meta-analysis. Mol Psychiatry, 2022; 27(3):1562–1572.
22.
FeiginA, KurlanR, McdermottMP, et al.A controlled trial of Deprenyl in children with Tourette’s syndrome and attention deficit hyperactivity disorder. Neurology 1997, 1996; 46(4):965–968.
23.
GadowKD, SverdJ, NolanEE, et al.Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. J Am Acad Child Adolesc Psychiatry, 2007; 46(7):840–848.
24.
GormanDA, ThompsonN, PlessenKJ, et al.Psychosocial outcome and psychiatric comorbidity in older adolescents with Tourette syndrome: Controlled study. Br J Psychiatry, 2010; 197(1):36–44.
25.
GradosMA, MathewsCA, Tourette Syndrome Association International Consortium for Genetics. Latent class analysis of Gilles de la Tourette syndrome using comorbidities: Clinical and genetic implications. Biol Psychiatry, 2008; 64(3):219–225.
26.
HirschtrittME, LeePC, PaulsDL, et al.Tourette Syndrome Association International Consortium for Genetics. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry, 2015; 72(4):325–333.
27.
HoekstraPJ, SteenhuisMP, TroostPW, et al.Relative contribution of attention-deficit hyperactivity disorder, obsessive-compulsive disorder, and tic severity to social and behavioral problems in tic disorders. J Dev Behav Pediatr, 2004; 25(4):272–279.
28.
HuttonB, SalantiG, CaldwellDM, et al.The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med, 2015; 162(11):777–784.
29.
JaffeRJ, CoffeyBJ. Pharmacologic treatment of comorbid attention-deficit/hyperactivity disorder and Tourette and tic disorders. Child Adolesc Psychiatr Clin N Am, 2022; 31(3):469–477.
30.
KhalifaN, Von KnorringAL. Psychopathology in a Swedish population of school children with tic disorders. J Am Acad Child Adolesc Psychiatry, 2006; 45(11):1346–1353.
31.
KrahnU, BinderH, KönigJ. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol, 2013; 13:35.
32.
LebowitzER, MotlaghMG, KatsovichL, et al.Tourette Syndrome Study Group. Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry, 2012; 21(8):451–457.
33.
LeckmanJF, KingRA, BlochMH. Clinical features of Tourette syndrome and tic disorders. J Obsessive Compuls Relat Disord, 2014; 3(4):372–379.
34.
LeckmanJF, RiddleMA, HardinMT, et al.The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry, 1989; 28(4):566–573.
35.
LeuchtS, ChaimaniA, CiprianiA, et al.Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci, 2016; 266(6):477–480.
36.
ManKKC, HägeA, BanaschewskiT, et al.ADDUCE Consortium. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Lancet Psychiatry, 2023; 10(5):323–333.
37.
McguireJF, PiacentiniJ, BrennanEA, et al.A meta-analysis of behavior therapy for Tourette Syndrome. J Psychiatr Res, 2014; 50:106–112.
38.
Morand-BeaulieuS, GrotS, LavoieJ, et al.The puzzling question of inhibitory control in Tourette syndrome: A meta-analysis. Neurosci Biobehav Rev, 2017; 80:240–262.
39.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: Diagnosis and management NICE guideline [NG87]. 2018. Available from: https://www.nice.org.uk/guidance/ng87
40.
NikolakopoulouA, HigginsJPT, PapakonstantinouT, et al.CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med, 2020; 17(4):E1003082.
41.
PringsheimT, OkunMS, Müller-VahlK, et al.Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 2019; 92(19):896–906.
42.
R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.
43.
RhodesKM, TurnerRM, HigginsJP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol, 2015; 68(1):52–60.
44.
RobertsonMM, EapenV, SingerHS, et al.Gilles de la Tourette syndrome. Nat Rev Dis Primers, 2017; 3:16097.
45.
RoessnerV, EicheleH, SternJS, et al.European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: Pharmacological treatment. Eur Child Adolesc Psychiatry, 2022; 31(3):425–441.
46.
RückerG, KrahnU, KönigJ, et al.netmeta: Network Meta-Analysis using Frequentist Methods. R package version 1.5-0. 2021.
47.
RückerG, SchwarzerG. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol, 2015; 15:58.
48.
SalantiG. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods, 2012; 3(2):80–97.
49.
ScahillL, ChappellPB, KimYS, et al.A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry, 2001; 158(7):1067–1074.
50.
SingerHS, BrownJ, QuaskeyS, et al.The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: A double-blind placebo-controlled study with clonidine and desipramine. Pediatrics, 1995; 95(1):74–81.
51.
SpencerT, BiedermanJ, CoffeyB, et al.A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 2002; 59(7):649–656.
52.
SterneJAC, SavovićJ, PageMJ, et al.RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 2019; 366:l4898.
53.
SukhodolskyDG, ScahillL, ZhangH, et al.Disruptive behavior in children with Tourette’s syndrome: Association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry, 2003; 42(1):98–105.
54.
SukhodolskyDG, WoodsDW, PiacentiniJ, et al.Moderators and predictors of response to behavior therapy for tics in Tourette syndrome. Neuorology, 2017; 88(11):1029–1036.
55.
Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 2002; 58:527–536.
56.
TurnerRM, DaveyJ, ClarkeMJ, et al.Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol, 2012; 41(3):818–827.
57.
WerryJS, BiedermanJ, ThistedR, et al.Resolved: Cardiac arrhythmias make desipramine an unacceptable choice in children. J Am Acad Child Adolesc Psychiatry, 1995; 34(9):1239–1248.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
